Matt Kapusta, uniQure CEO (via website)
UniQure gets another shot with hemophilia gene therapy after FDA lifts clinical hold; Neoleukin's IL-2 hopeful also cleared
Months after a disastrous clinical hold on its hemophilia B gene therapy shut down development, uniQure had reason to believe its drug wasn’t to blame …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.